Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can vitamin e cream soothe Chemo's painful skin side effect?

NCT ID NCT05939726

Symptom relief Sponsor: Sarawak General Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding a moisturizing cream with or without vitamin E (from palm oil) to a standard urea-based cream helps resolve hand-foot skin reactions caused by the chemotherapy drug capecitabine. 145 cancer patients with mild skin reactions took part. The goal was to see if these creams could clear the rash faster or prevent it from getting worse.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

145 people

The number who actually took part.

Started

May 2023

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18 years old and above 2. Able to give written consent freely 3. Receiving capecitabine at least 1 dose, as monotherapy or in combination therapy 4. Receiving urea-based cream 5. Developed PPE of NCI-CTCAE grade 1 6. Have at least three cycles of chemotherapy to complete 7. Life expectancy ≥ 6 months 8. ECOG≤2 Exclusion Criteria: 1. Unable to understand the information sheet and informed consent form 2. Allergy history towards vitamin E and its isoforms or any components of the investigational products 3. Unable to tolerate urea-based products 4. Other pre-existing dermatological diseases or conditions that may interfere the evaluation of PPE 5. PPE complicated with infection 6. Receiving other agent(s) that are known to cause PPE or hand- foot syndrome and hand-foot skin reactions 7. Receiving long-term topical or systemic steroid treatment (except as part of pre-or post-medications of chemotherapy regime) 8. Pregnant or lactating mother 9. Participating in another interventional trial 10. Refuses to interrupt his/her usual care 11. Anticipated inability to follow-up

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Palmar-plantar erythrodysesthesia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hand-foot syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Palmar-plantar erythrodysesthesia Palmar-plantar erythrodysesthesia due to cytotoxic therapy

Contacts and locations

Locations

  • Sarawak General Hospital

    Kuching, Sarawak, 93586, Malaysia